Patents by Inventor Anil K. Sood

Anil K. Sood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230167453
    Abstract: Provided herein are RNA aptamers targeting CD5L. Further provided herein are methods of use thereof for the treatment of a disease or disorder, such as cancer.
    Type: Application
    Filed: April 1, 2021
    Publication date: June 1, 2023
    Applicants: Board of Regents, The University of Texas System, Consiglio Nazionale delle Ricerche
    Inventors: Anil K. SOOD, Paola AMERO, Gabriel LOPEZ-BERESTEIN, Vittorio DE FRANCISCIS
  • Publication number: 20220380766
    Abstract: Provided herein are DNA aptamers targeting AXL receptor kinase. The DNA aptamers may comprise a thiophosphate backbone and be chemically modified. Further provided herein are methods of use thereof for the treatment of a disease or disorder, such as cancer.
    Type: Application
    Filed: December 16, 2019
    Publication date: December 1, 2022
    Applicants: Board of Regents, The University of Texas System, Consiglio Nazionale delle Ricerche
    Inventors: Gabriel LOPEZ-BERESTEIN, Paola AMERO, Cristian RODRIGUEZ-AGUAYO, Rahul MITRA, Anil K. SOOD, Vittorio DE FRANCISCIS, David VOLK, Lokesh Ganesh L. RAO
  • Publication number: 20220163532
    Abstract: The present invention provides that exosomes from ovarian cancer patients contain nuclear proteins and genomic DNA at an increased proportion. As such, detecting nuclear-derived exosomes provides a method of early detection of ovarian cancer. Furthermore, the level of nuclear-derived exosomes can be monitored over time to assess responsiveness to genotoxic therapy.
    Type: Application
    Filed: March 27, 2020
    Publication date: May 26, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventors: Anil K. SOOD, Akira YOKOI
  • Patent number: 11090266
    Abstract: The present invention discloses c-MYC-siRNA formulation as a potential therapeutic target for cisplatin-resistant ovarian cancer. It is disclosed targeting c-MYC with small interfering RNA (siRNA) in the cisplatin-resistant ovarian cancer cell line inducing a significant cell growth arrest and inhibition of cell proliferation. Apoptosis and arrest of cell cycle progression were also observed after c-MYC-siRNA-based silencing of c-MYC. Furthermore, delivering nanoliposomal c-MYC-siRNA, decreased tumor weight and number of tumor nodules compared with a liposomal-negative control siRNA.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: August 17, 2021
    Inventors: Pablo E. Vivas-Mejia, Jeyshka M. Reyes Gonzalez, Anil K. Sood
  • Publication number: 20210130450
    Abstract: Isolated or recombinant anti-EGFL6 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.
    Type: Application
    Filed: November 12, 2020
    Publication date: May 6, 2021
    Inventors: Ningyan ZHANG, Zhiqiang AN, Anil K. SOOD
  • Patent number: 10875912
    Abstract: Isolated or recombinant anti-EGFL6 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: December 29, 2020
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Ningyan Zhang, Zhiqiang An, Anil K. Sood
  • Patent number: 10874622
    Abstract: Disclosed are nanoparticles for the delivery of a therapeutic agent or a diagnostic agent to a subject that include a chitosan and a polyphosphate, wherein the chitosan nanoparticles are coated with polylactic acid. Methods of delivering a therapeutic agent or a diagnostic agent to a subject for the treatment or prevention of a disease are also disclosed. For example, the treatment of ovarian cancer in a subject by inhibiting the expression of ZNF034 is disclosed.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: December 29, 2020
    Assignee: Board of Regents, The University of Texas System
    Inventors: Burcu Aslan, Gabriel Lopez-Berestein, Anil K. Sood
  • Publication number: 20200179284
    Abstract: The present invention discloses c-MYC-siRNA formulation as a potential therapeutic target for cisplatin-resistant ovarian cancer. It is disclosed targeting c-MYC with small interfering RNA (siRNA) in the cisplatin-resistant ovarian cancer cell line inducing a significant cell growth arrest and inhibition of cell proliferation. Apoptosis and arrest of cell cycle progression were also observed after c-MYC-siRNA-based silencing of c-MYC. Furthermore, delivering nanoliposomal c-MYC-siRNA, decreased tumor weight and number of tumor nodules compared with a liposomal-negative control siRNA.
    Type: Application
    Filed: February 3, 2020
    Publication date: June 11, 2020
    Inventors: Pablo E. Vivas-Mejia, Jeyshka M. Reyes Gonzalez, Anil K. Sood
  • Publication number: 20200069594
    Abstract: Provided herein are lipid-based nanoparticles (e.g., exosomes) having (a) a core comprising a cationic polymer and a therapeutic agent (e.g., a therapeutic protein, an antibody, an inhibitory RNA, and/or a small molecule drug) and (b) a lipid coating comprising an exosomes-derived membrane. Furthermore, the present invention provides methods of producing such nanoparticles as well as methods for use of such lipid-based nanoparticles in therapy.
    Type: Application
    Filed: December 8, 2017
    Publication date: March 5, 2020
    Applicant: Board of Regents, The University of Texas System
    Inventors: Anil K. SOOD, Sherry Y. WU, Gabriel LOPEZ-BERESTEIN
  • Patent number: 10548842
    Abstract: The present invention discloses c-MYC-siRNA formulation as a potential therapeutic target for cisplatin-resistant ovarian cancer. It is disclosed targeting c-MYC with small interfering RNA (siRNA) in the cisplatin-resistant ovarian cancer cell line inducing a significant cell growth arrest and inhibition of cell proliferation. Apoptosis and arrest of cell cycle progression were also observed after c-MYC-siRNA-based silencing of c-MYC. Furthermore, delivering nanoliposomal c-MYC-siRNA, decreased tumor weight and number of tumor nodules compared with a liposomal-negative control siRNA.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: February 4, 2020
    Inventors: Pablo E. Vivas-Mejia, Jeyshka M. Reyes Gonzalez, Anil K. Sood
  • Publication number: 20190031751
    Abstract: Isolated or recombinant anti-EGFL6 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.
    Type: Application
    Filed: February 6, 2017
    Publication date: January 31, 2019
    Applicant: The Board of Regents of the University of Texsas System
    Inventors: Ningyan ZHANG, Zhiqiang AN, Anil K. SOOD
  • Publication number: 20180185284
    Abstract: The present invention discloses c-MYC-siRNA formulation as a potential therapeutic target for cisplatin-resistant ovarian cancer. It is disclosed targeting c-MYC with small interfering RNA (siRNA) in the cisplatin-resistant ovarian cancer cell line inducing a significant cell growth arrest and inhibition of cell proliferation. Apoptosis and arrest of cell cycle progression were also observed after c-MYC-siRNA-based silencing of c-MYC. Furthermore, delivering nanoliposomal c-MYC-siRNA, decreased tumor weight and number of tumor nodules compared with a liposomal-negative control siRNA.
    Type: Application
    Filed: February 20, 2018
    Publication date: July 5, 2018
    Inventors: Pablo E. Vivas-Mejia, Jeyshka M. Reyes Gonzalez, Anil K. Sood
  • Publication number: 20180169029
    Abstract: Disclosed are nanoparticles for the delivery of a therapeutic agent or a diagnostic agent to a subject that include a chitosan and a polyphosphate, wherein the chitosan nanoparticles are coated with polylactic acid. Methods of delivering a therapeutic agent or a diagnostic agent to a subject for the treatment or prevention of a disease are also disclosed. For example, the treatment of ovarian cancer in a subject by inhibiting the expression of ZNF034 is disclosed.
    Type: Application
    Filed: June 23, 2016
    Publication date: June 21, 2018
    Inventors: Burcu ASLAN, Gabriel LOPEZ-BERESTEIN, Anil K. SOOD
  • Patent number: 9895312
    Abstract: The present invention discloses c-MYC-siRNA formulation as a potential therapeutic target for cisplatin-resistant ovarian cancer. It is disclosed targeting c-MYC with small interfering RNA (siRNA) in the cisplatin-resistant ovarian cancer cell line inducing a significant cell growth arrest and inhibition of cell proliferation. Apoptosis and arrest of cell cycle progression were also observed after c-MYC-siRNA-based silencing of c-MYC. Furthermore, delivering nanoliposomal c-MYC-siRNA, decreased tumor weight and number of tumor nodules compared with a liposomal-negative control siRNA.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: February 20, 2018
    Inventors: Pablo E. Vivas-Mejia, Jeyshka M. Reyes Gonzalez, Anil K. Sood
  • Publication number: 20160375050
    Abstract: Disclosed are nanoparticles for the delivery of a therapeutic agent or a diagnostic agent to a subject that include a chitosan and a polyphosphate, wherein the weight ratio of the chitosan to the polyphosphate is about 1.0 or greater and the weight ratio of the polyphosphate to the therapeutic agent or diagnostic agent is about 15.0 or less. Also disclosed are nanoparticles that include a chitosan and an inhibitor of enhancer of Zeste homologue 2 (EZH2). Methods of delivering a therapeutic agent or a diagnostic agent to a subject for the treatment or prevention of a disease and methods of predicting prognosis of ovarian cancer in a subject that involve determining the expression and/or function of EZH2 in the subject are also disclosed.
    Type: Application
    Filed: September 13, 2016
    Publication date: December 29, 2016
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Gabriel LOPEZ-BERESTEIN, Eylem G√úVEN, Angela SANGUINO, Anil K. SOOD, Emir Baki DENKBAS
  • Patent number: 8895717
    Abstract: The present invention relates to the fields of molecular biology and drug delivery. In certain embodiments, the present invention provides methods for the delivery of a siNA (e.g., a siRNA) to a cell via a neutral (non-charged) liposome. These methods may be used to treat a disease, such as cancer.
    Type: Grant
    Filed: April 17, 2006
    Date of Patent: November 25, 2014
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Anil K. Sood, Gabriel Lopez-Berestein, Charles N. Landen, Arturo Chavez-Reyes
  • Patent number: 8734853
    Abstract: Disclosed are high density lipoprotein-nucleic acid particles, wherein the particles include (a) an apolipoprotein; (b) a nucleic acid component comprising a therapeutic nucleic acid segment; and (c) a polypeptide comprising a positively charged region, wherein the positively-charged region of the polypeptide associates with the nucleic acid component. Also disclosed are pharmaceutical compositions that include a) an apolipoprotein; (b) a nucleic acid component comprising a therapeutic nucleic acid segment; and (c) a polypeptide comprising a positively charged region. Methods that concern the particles and pharmaceutical compositions of the present invention are also set forth, as well as kits.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: May 27, 2014
    Assignees: University of North Texas Health Science Center at Fort Worth, The Board of Regents, The University of Texas System
    Inventors: Anil K. Sood, Andras G. Lacko, Gabriel Lopez-Berestein, Lingegowda S. Mangala, Walter J. McConathy, Laszlo Prokai, Maya P. Nair
  • Publication number: 20140127326
    Abstract: Provided are methods for detecting a cancer, such as an ovarian cancer. In certain aspects, the methods involve detecting or measuring one or more volatile organic compounds (VOCs) from the breath of a subject. Apparatuses for the collection of VOCs are provided.
    Type: Application
    Filed: March 5, 2012
    Publication date: May 8, 2014
    Inventors: Anil K. Sood, Alpa M. Nick, Edward A. Felix
  • Patent number: 8466154
    Abstract: This application describes a novel technology in drug discovery and drug-based imaging/detection: the wrapping technology. This technology is based on identified singularities in the structure of soluble proteins. In contrast with drug-design approaches based on standard structural considerations, the packing of a protein, or more precisely, its dehydron pattern, may be used as a selectivity filter to design small-molecule inhibitors. The wrapping technology described herein is a novel form of rational drug design for avoiding side effects in drug therapy and sharpening the inhibitory impact of drugs on the oncokinome.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: June 18, 2013
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Ariel Fernandez, William Bornmann, Gabriel Lopez-Berestein, Angela Sanguino, Zheng-Hong Peng, Anil K. Sood
  • Publication number: 20130131076
    Abstract: This application describes a novel technology in drug discovery and drug-based imaging/detection: the wrapping technology. This technology is based on identified singularities in the structure of soluble proteins. In contrast with drug-design approaches based on standard structural considerations, the packing of a protein, or more precisely, its dehydron pattern, may be used as a selectivity filter to design small-molecule inhibitors. The wrapping technology described herein is a novel form of rational drug design for avoiding side effects in drug therapy and sharpening the inhibitory impact of drugs on the oncokinome.
    Type: Application
    Filed: October 29, 2007
    Publication date: May 23, 2013
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Ariel Fernandez, William Bornmann, Gabriel Lopez-Berestein, Angela Sanguino, Zheng-Hong Peng, Anil K. Sood